As director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer), my focus is integrating patient, model system, and high-content single cell genomics data to translate clinically observed correlations into a mechanistic understanding of the physical and biological underpinnings of cancer dynamics to modify outcomes for the diagnosis, prognosis, and therapy management of ovarian, breast, lung, colon, prostate, other tissue cancers, multiple myeloma, and other cancers. The underlying technology of the center is now being tested in the research setting as well as being clinically developed by Epic Sciences. Three complementary research projects at CSI-Cancer are supported by one shared resource core to address the laboratory’s aims of i) patient health and performance assessment for better care strategy; 2) disease forecasting and prognosis for improved confidence in decision making; and 3) disease characterization at the molecular level for predicting and monitoring the therapeutic response.